Cancer cells rely on the enzyme telomerase (EC 2.7.7.49) to promote cellular immortality. Telomerase inhibitors (i.e., azidothymidine) can represent promising antitumor agents, although showing high toxicity when administered alone. Better outcomes were observed within a multipharmacological approach instead. In this context, we exploited the validated antitumor targets carbonic anhydrases (CAs; EC 4.2.1.1) IX and XII to attain the first proof of concept on CA-telomerase dual-hybrid inhibitors. Compounds <b>1b</b>, <b>7b</b>, <b>8b</b>, and <b>11b</b> showed good in vitro inhibition potency against the CAs IX and XII, with <i>K</i><sub>I</sub> values in the low nanomolar range, and strong antitelomerase activity in PC-3 and HT-29 cells (IC<sub>50</sub> values ranging from 5.2 to 9.1 μM). High-resolution X-ray crystallography on selected derivatives in the adduct with hCA II as a model study allowed to determine their binding modes and thus to set the structural determinants necessary for further development of compounds selectively targeting the tumoral cells.